Harrow (NASDAQ:HROW) Price Target Raised to $60.00

Harrow (NASDAQ:HROW) had its price target increased by HC Wainwright from $57.00 to $60.00 in a research report released on Monday,Benzinga reports. The brokerage currently has a buy rating on the stock. HC Wainwright also issued estimates for Harrow’s Q2 2025 earnings at $0.03 EPS, Q4 2025 earnings at $0.10 EPS and FY2026 earnings at $0.40 EPS.

Separately, B. Riley reduced their target price on shares of Harrow from $69.00 to $65.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st.

Harrow Trading Down 4.3%

Shares of Harrow stock opened at $25.13 on Monday. The company has a debt-to-equity ratio of 3.23, a current ratio of 1.55 and a quick ratio of 1.44. The stock’s 50 day simple moving average is $24.85 and its 200-day simple moving average is $32.27. The stock has a market cap of $921.89 million, a P/E ratio of -26.73 and a beta of 0.41. Harrow has a 1-year low of $15.78 and a 1-year high of $59.23.

Harrow (NASDAQ:HROW) last released its quarterly earnings data on Thursday, May 8th. The company reported ($0.38) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.40). The company had revenue of $47.83 million for the quarter, compared to analyst estimates of $57.00 million. Harrow had a negative return on equity of 45.57% and a negative net margin of 19.75%. Analysts predict that Harrow will post -0.53 EPS for the current fiscal year.

Institutional Trading of Harrow

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Barclays PLC boosted its stake in shares of Harrow by 301.9% in the third quarter. Barclays PLC now owns 52,593 shares of the company’s stock valued at $2,365,000 after purchasing an additional 39,506 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Harrow by 443.1% in the third quarter. JPMorgan Chase & Co. now owns 238,367 shares of the company’s stock valued at $10,717,000 after buying an additional 194,480 shares during the last quarter. Brookstone Capital Management acquired a new stake in shares of Harrow during the fourth quarter worth $275,000. SG Americas Securities LLC lifted its position in Harrow by 158.5% in the fourth quarter. SG Americas Securities LLC now owns 30,689 shares of the company’s stock valued at $1,030,000 after purchasing an additional 18,815 shares during the period. Finally, Sonora Investment Management Group LLC acquired a new position in Harrow during the fourth quarter worth $518,000. 72.76% of the stock is currently owned by hedge funds and other institutional investors.

Harrow Company Profile

Harrow, Inc operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business. The company was formerly known as Imprimis Pharmaceuticals, Inc and changed its name to Harrow Health, Inc in December 2018. Harrow Health, Inc was incorporated in 2006 and is headquartered in Nashville, Tennessee.